Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Common Equity of -$291 million for Q2 2026, compared with $151 million a year earlier.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Ultragenyx Pharmaceutical posted Common Equity of -$80 million.
- By year, Common Equity came in at $255 million in FY2024 (-7.3%), $275 million in FY2023 (-21.9%), $352 million in FY2022 (-61.8%) and $922.56 million in FY2021 (-20.1%).
- The Q2 2026 figure ranks as the lowest quarterly Common Equity in data going back to Q4 2013.
- Year over year, Common Equity gained in two of the last five quarters, with growth averaging 165.3%.
- The high point for year-over-year Common Equity in five years was Q3 2024 (growth of 993.6%); the low point was Q3 2025 (a decline of 97.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at -$236 million (Q1 2026), -$80 million (Q4 2025) and $9.16 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Ultragenyx Pharmaceutical | 1.51 Bn | -292.70 Mn | 180.00 Mn | -291.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -291.00 Mn |
| Mar 31, 2026 | -236.00 Mn |
| Dec 31, 2025 | -80.00 Mn |
| Sep 30, 2025 | 9.16 Mn |
| Jun 30, 2025 | 151.00 Mn |
| Mar 31, 2025 | 144.00 Mn |
| Dec 31, 2024 | 255.00 Mn |
| Sep 30, 2024 | 346.83 Mn |
| Jun 30, 2024 | 432.42 Mn |
| Mar 31, 2024 | 140.26 Mn |
| Dec 31, 2023 | 275.00 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Jun 30, 2023 | 129.03 Mn |
| Mar 31, 2023 | 220.48 Mn |
| Dec 31, 2022 | 352.00 Mn |
| Sep 30, 2022 | 468.83 Mn |
| Jun 30, 2022 | 678.07 Mn |
| Mar 31, 2022 | 796.42 Mn |
| Dec 31, 2021 | 922.56 Mn |
| Sep 30, 2021 | 933.67 Mn |
API Access
Ultragenyx Pharmaceutical Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();